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A Nationwide Survey of Lymphangioleiomyomatosis in Korea: 
Recent Increase in Newly Diagnosed Patients 
In 2007, the Korean Interstitial Lung Disease Society had collected clinical data of 
patients who have diagnosed as Lymphangioleiomyomatosis (LAM) since 1990 through 
nationwide survey, which showed that LAM patients had increased sharply after 2004. 
The present study was performed to show the clinical features of Korean patients with 
LAM, and to establish the reason for the recent increase in the diagnosis. All 63 patients 
were women and the mean age at diagnosis was 36 yr. The most common presenting 
symptom was dyspnea and 8 patients had tuberous sclerosis complex. The survival rate 
at 5 yr after diagnosis was 84%. Compared with patients diagnosed after 2004 (n=34), 
the patients diagnosed before 2004 (n=29) complained with dyspnea more (P=0.016) 
and had lower FEV1% predicted (P=0.003), and DLco% predicted (P=0.042). The higher 
proportion of patients diagnosed after 2004 showed the normal chest radiography, 
and they were detected by routine chest CT screening (P=0.016). This study showed 
that clinical features of Korean patients with LAM were not different from those 
reported elsewhere. It is concluded that the reason for the increase of newly diagnosed 
patients is the result of increase in detection of the early stage LAM by the widespread 
use of chest CT screening.
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ORIGINAL ARTICLE
Respiratory Diseases
INTRODUCTION
Lymphangioleiomyomatosis (LAM) is a rare disease that occurs 
mainly in women of reproductive age. The clinical features, in-
cluding recurrent spontaneous pneumothorax, slow progres-
sive dyspnea, hemoptysis, chylothorax, and chylous ascites, re-
sult from progressive cystic lung destruction and accumulation 
of smooth muscle cells (LAM cells) in the lungs and axial lym-
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phatics (1-4). The primary treatment for LAM consists of hor-
monal therapy and supportive management, although the re-
sponse to hormonal therapy has not yet been demonstrated 
conclusively (4-6). 
 In 2007, the Korean Interstitial Lung Disease Society had col-
lected data for patients diagnosed with LAM, by a nationwide 
survey, to establish their demographic, clinical, and radiograph-
ic features. This survey showed that the number of new patients 
with LAM had increased sharply after 2004 (Fig. 1). Therefore, 
the present study aimed to understand the initial clinical radio-
logical findings, management, and clinical course of patients 
with LAM in Korea. We also aimed to establish the reason for 
the recent increase in newly diagnosed patients by comparing 
the clinical and radiographic features between patients diag-
nosed with LAM before and after 2004. 
MATERIALS AND METHODS
Study population and data collection
We enrolled 63 patients diagnosed with LAM between 1990 and 
2007 in Korea. The nationwide survey was performed by collect-
ing the questionnaire-based data sheet between May and Sep-
tember 2007. The data sheet included age at diagnosis, smoking 
history, previous history of pneumothorax or pleural effusion, 
presence of tuberous sclerosis complex (TSC) or angiomyoli-
poma (AML), initial clinical and radiological presentation, co-
morbidity, initial pulmonary function tests, method of diagnosis, 
treatment modalities, and survival, and we reviewed retrospec-
tively all items on the data sheets. The diagnosis of LAM was 
made by lung pathology or typical chest high-resolution com-
puted tomography (HRCT) findings, along with compatible clin-
ical history. Pathologically, LAM was diagnosed in 39 patients 
(62%), which was based on the results of surgical lung biopsies 
(n=33), transbronchial lung biopsies (n=4), excisional biopsy of 
retroperitoneal mass (n=1), or inguinal lymph node biopsy (n= 
1). In the remaining 24 patients (48%), the diagnosis of LAM was 
established from typical HRCT findings, which are diffuse, thin-
walled cysts scattered in an even distribution throughout the 
lung fields, with normal intervening lung parenchyma (1).
 Survival status was obtained from the death registry of the 
Korea National Statistical Office as of December 2007. This study 
was approved by the Institutional Review Board of the Samsung 
Medical Center (IRB approval number: 2009-12-066). 
Statistical analysis
Values are expressed as number (percentile), mean±standard 
deviation or median (range). Statistical analysis was performed 
using the unpaired Student’s t test for continuous variables and 
the chi-squared or Fisher’s exact test for categorical values, as 
appropriate. Survival was calculated from the time of diagnosis 
of LAM until the endpoint (December 2007). Survival probabil-
ity according to disease duration was estimated by the Kaplan–
Meier method. All P values were two-sided, with P<0.05 con-
sidered to be statistically significant. Statistical analysis was per-
formed using PASW version 17.0 (SPSS Inc., Chicago, IL, USA). 
RESULTS
Demographic and clinical characteristics
All 63 patients were women, and the mean age at diagnosis was 
36 yr (range, 19–65). The age at diagnosis was >40 yr in 35% of 
the patients. Three patients were ex-smokers and one was a cur-
rent smoker. The most common past or coexisting disease was 
pulmonary tuberculosis (11%). AML was found in 21 patients 
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Fig. 1. Annual number of new patients diagnosed with LAM.
Table 1. Demographic and clinical features of 63 patients with LAM
Characteristic
All patients 
(n=63)
Patients before 
2004 (n=29)
Patients after 
2004 (n=34)
P 
value‡
Age at diagnosis, years 36±11 36±10 37±12 0.709
Smoking status, No. (%) 0.504
   Never-smokers
   Ex-smokers
   Current smokers
59 (94)
3 (5)
1 (2)
27 (93)
1 (3)
1 (3)
32 (94)
2 (6)
0 (0)
Presence of TSC  8 (13) 4 (14) 4(12) 1.000
Past or coexisting illness, No. (%)
   Tuberculosis
   Malignancy*
   Hypertension
   Viral hepatitis
   Diabetes mellitus
   Other†
7 (11)
5 (8)
2 (3)
2 (3)
1 (2)
3 (5)
5 (17)
2 (7)
1 (3)
0 (0)
1 (3)
1 (3)
2 (6)
3 (9)
1 (3)
2 (6)
0 (0)
2 (6)
0.233
1.000
1.000
0.495
0.460
1.000
Symptoms at presentation, No. (%)
   Dyspnea
   Chest discomfort
   Frequent cough
   Hemoptysis
   Pneumothorax
53 (84)
22 (35)
21 (33)
7 (11)
27 (43)
28 (97)
7 (24)
13 (45)
5 (17)
11 (38)
25 (74)
15 (44)
8 (24)
2 (6)
16 (47)
0.016
0.097
0.074
0.237
0.466
*Malignancy includes advanced gastric carcinoma, papillary thyroid carcinoma, breast 
cancer, cervical carcinoma, and multiple myeloma; †Other includes nephrotic synd- 
rome, atrial septal defect, and hypothyroidism; ‡P values are for comparison between 
the patients diagnosed before and after 2004. 
LAM, lymphangioleiomyomatosis; TSC, tuberous sclerosis complex.
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(33%), and eight (13%) had TSC. The main presenting symptom 
was dyspnea (84%). Pneumothorax was observed in 43% of the 
patients at diagnosis, and 63% had a previous history of pneu-
mothorax. The median number of patients who experienced at 
least one episode of pneumothorax was three (range, 1–10). 
 Twenty-nine patients were diagnosed with LAM before 2004, 
and the remaining 34 patients were diagnosed after that date. 
No significant difference existed between the groups for age, 
history of smoking, and presence of TSC. However, exertional 
dyspnea was more frequent in the patients diagnosed before 
than after 2004 (97% vs. 74%; P=0.016; Table 1).
Pulmonary function tests
Baseline pulmonary function tests were performed <6 months 
before or after diagnosis of LAM (Table 2). Spirometry results 
were normal in 19 of 44 patients whose data were available. The 
mean values for forced vital capacity (FVC) % predicted, forced 
expiratory volume in 1 second (FEV1) % predicted (both n=44), 
total lung capacity (TLC) % predicted (n=24), and diffusing ca-
pacity of carbon monoxide (DLCO) % predicted (n=34) were 
82.5, 75.8, 99.3, and 74.2, respectively (Table 2). When lung func-
tion was compared between patients diagnosed before and after 
2004, those diagnosed before 2004 had more severe impairment 
in FEV1 % predicted (60.3 vs. 85.5, P=0.003), FEV1/FVC ratio (60.5 
vs. 83.8, P<0.001), and DLco % predicted (60.9 vs. 80.6, P=0.042; 
Table 2).
Radiological findings at the time of diagnosis
The main chest radiography finding was the presence of pneu-
mothorax (43%). The reticulonodular infiltration and presence 
of cysts or bulla upon chest radiography were more common in 
patients diagnosed before than after 2004 (48% vs. 15%, P=0.004 
and 41% vs. 15%, P=0.017), while normal chest radiographic 
appearance was more common in patients diagnosed after 2004 
than before (3% vs. 26%, P=0.017). All patients showed typical, 
thin-walled parenchymal cysts that were usually distributed 
homogeneously in both lung fields upon HRCT. Other abnor-
malities seen with HRCT included nodular densities in 13%, 
ground-glass opacities in 11%, pleural effusion in 13%, and peri-
cardial effusion in 3% (Table 3).
Treatment modalities and outcome
Several medical treatment modalities were tried in 35 patients. 
Seven of these patients received intramuscular medroxyproges-
terone (400 mg/month for a median duration of 19 months), 17 
received oral progesterone monotherapy (10–20 mg/day for a 
median duration of 19 months), and eight received oral proges-
terone with tamoxifen (median, 24 months). Among the remain-
ing three patients, one was taking gonadotropin-releasing hor-
mone agonist and two were taking rapamycin (Table 4). 
 Eight patients who received medical treatment underwent 
oophorectomy. Ten of 21 patients with AML were treated with 
surgical resection and four with arterial embolization. Of all pa-
Table 2. Baseline pulmonary function testsw
Characteristics
All patients Patients before 2004 Patients  after 2004
P value†
 No.* Mean±S.D.  No.* Mean±S.D.  No.* Mean±S.D.
FVC % predicted 44  82.5±23.3 17     76.8±23.8 27 86.0±22.8   0.203
FEV1 % predicted 44  75.8±28.5 17     60.3±28.7 27 85.5±24.1   0.003
FEV1/FVC ratio 44  74.8±19.3 17     60.5±14.6 27 83.8±16.3 <0.001
TLC % predicted 24  99.3±11.7   6 105.5±7.0 18 97.2±12.4   0.139
DLCO % predicted 34 74. 2±26.7 11     60.9±27.7 23 80.6±24.3   0.042
*Number of patients with information available; †P values are for comparison between the patients diagnosed before and after 2004.
FVC, forced vital capacity; FEV1, forced expiratory volume in one second; TLC, total lung capacity; DLCO, diffusing capacity of carbon monoxide.
Table 3. Radiographic finding at the time of diagnosis
Findings All patients 
Patients 
before 2004
Patients 
after 2004
P 
value*
Chest X-ray, No. (%) 63 29 34
   Normal appearance
   Reticulonodular infiltrates
   Pneumothorax
   Cysts or bullae
   Pleural effusion
10 (16)
19 (30)
27 (43)
17 (27)
  7 (11)
1 (3)
14 (48)
11 (38)
12 (41)
  3 (10)
  9 (27)
  5 (15)
16 (47)
  5 (15)
  4 (12)
0.016
0.004
0.466
0.017
1.000
HRCT scan, No. (%) 63 29 34
   Multiple cysts in both lung
   Nodular densities
   Ground-glass opacities
   Pleural effusion
   Pericardial effusion
  63 (100)
  8 (13)
  7 (11)
  8 (13)
2 (3)
  29 (100)
2 (7)
  6 (21)
  3 (10)
1 (3)
  34 (100)
  5 (15)
1 (3)
  5 (15)
1 (3)
-
0.437
0.042
0.716
1.000
*P values are for comparison between patients diagnosed before and after 2004.
HRCT, high resolution computed tomography.
Table 4. Modality of hormonal therapy in 63 patients with LAM
Treatment modalities No. (%) Dose
Median of 
duration 
(range), months
Surgical treatment*
   Bilateral oophorectomy   8 (13)
Medical treatment 35 (56)
   Medroxyprogesterone
      Intramuscular
      Oral
      Oral+tamoxifen 
  7 (11)
17 (27)
  8 (13)
400 mg/month
10–20 mg/day
5–20 mg/day+ 
20 mg/day
19 (2–91)
  19 (3–180)
  24 (6–173)
   Leuprolide (S.C) 1 (2) 3.75 mg/month 6
   Rapamycin 2 (3) 1 mg/day 14 (7–21)
No treatment 28 (44)
*All subjects for surgical treatment received medical treatment.
S.C, subcutaneously.
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tients, two patients underwent lung transplantation. One of 
these patients underwent left lung transplantation and died 
from chronic graft-versus-host disease at 38 months after trans-
plantation. The other patient is still being followed-up, since 
April 2007.
Disease course and survival
During follow-up, 12 patients died within a median duration of 
60 months (1–144 months). Cause of death was attributed to 
LAM in all patients, directly from respiratory failure (n=11) and 
lung transplantation morbidity (n=1). The survival probability, 
evaluated by the Kaplan–Meier method, is shown in Fig. 2. The 
probability of being alive was 84% at 5 yr and 65% at 8.5 yr after 
diagnosis.  
DISCUSSION
This report provided the clinical and radiological features, and 
therapeutic modalities of patients with LAM in Korea. The clini-
cal features of Korean patients with LAM do not differ from those 
reported elsewhere and we also found that the patients recently 
diagnosed as LAM can be detected at the early stage with mild 
respiratory symptoms and lung impairment by frequent use of 
chest CT screening. 
 Recently, a large number of patients with LAM have been re-
ported (7, 8). These reports have demonstrated that the age range 
of women with LAM was broader, and normal spirometry at di-
agnosis was more common than previously reported (2, 9). In 
addition, the clinical course of these patients with LAM was 
better than that described earlier, when the majority of patients 
died from respiratory failure, usually within 10 yr after the ap-
parent onset of the disease (2, 10, 11).
 According to the present Korea nationwide survey conduct-
ed for patients diagnosed as LAM between 1990 and 2007, the 
number of LAM patients showed a tendency to increase and it 
is noticeable that the number of patient newly diagnosed as LAM 
increased rapidly after 2004 (Fig. 1). In this nationwide survey, 
although the mean age at diagnosis was similar to that reported 
previously (2, 9, 12, 13), the age range (19–65 yr) was as broad 
as data shown in the National Heart, Lung and Blood Institute 
(NHLBI) registry of 2006. The most common presenting symp-
toms were exertional dyspnea and pneumothorax, which was 
consistent with other studies (8, 12). The prevalence of chylo-
thorax was 20–30% in previous studies (4, 8, 9), but in our study, 
chylothorax was seen in only one patient at initial diagnosis and 
in two more during the course of the disease.
 Nineteen patients were not available for pulmonary function 
tests because of dyspnea or pneumothorax at initial diagnosis, 
Fig. 2. Kaplan–Meier survival analysis of mortality of 63 patients with LAM. The 
probability of being alive was 84% at 5 yr and 65% at 8.5 yr after diagnosis.
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Fig. 3. Radiographic features of a 46-yr old woman with LAM. (A) Chest radiography of 46-yr old woman with LAM. Chest radiography discloses no clue to the cystic lung 
disease. (B) High resolution CT scan of 46-yr old woman with LAM. High resolution CT scan at the level of lower lobar bronchus shows innumerable ovoid or round cystic 
lesions (arrows) in both lungs. The walls of these cysts are thin and even in thickness, which were considered as typical morphologic features of LAM.
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but the overall pulmonary function was better when compared 
to that in previous studies (2, 9, 13). In patients newly diagnosed 
with LAM after 2004, FEV1 predicted, FEV1/FVC, and DLco were 
significantly higher than those in patients diagnosed before 2004. 
Declines in FEV1 and the FEV1/FVC ratio, which represent pro-
gressive obstructive defects, and decreased DLco are sensitive 
factors for disease progression in LAM (8). Therefore, we sug-
gest that patients diagnosed after 2004 were detected with mild 
lung impairment, which may mean that it was at an earlier stage 
compared to those diagnosed before 2004. This was consistent 
with the finding that clinical symptoms were significantly better, 
and normal radiographic findings were more frequent in recent-
ly diagnosed patients. This earlier detection of LAM in patients 
with mild symptoms and normal chest radiography might be 
explained by the widespread and liberal use of CT scanning, 
which is superior to chest radiography for the assessment of 
patients with LAM (14). In our study, among 10 patients with 
normal chest radiographic findings, seven were detected by CT 
screening (Fig. 3) and three without respiratory symptoms were 
diagnosed coincidentally for LAM, after undergoing CT scan-
ning for breast cancer, thyroid cancer, or abdominal pain. 
 In our nationwide survey, 56% of patients received medical 
therapy and the remainder did not receive it due to rejection of 
therapy for pregnancy or postmenopausal status, or they had no 
subjective symptoms. Although the beneficial effect of hormon-
al manipulation is inconclusive (2, 4, 8), it is the only therapeu-
tic option for LAM. However, a recent nonrandomized, open-
label trial showed that treatment with sirolimus was associated 
with improvement of lung function in sporadic LAM (15). Addi-
tional trials for the relative risks and benefits are needed; how-
ever, the use of sirolimus is expected to be promising in the treat-
ment of LAM. Thus, it might be helpful for the treatment of early-
detected patients with LAM who show mild symptoms and signs. 
 In the present study, Kaplan–Meier plots showed survival 
probabilities of 84% after 5 yr and 65% after 8.5 yr from the time 
of diagnosis. Previous studies have reported a 3-yr time differ-
ence between the time of onset of symptoms and diagnosis, and 
our result was therefore similar to that of Taylor et al. (4) and 
Urban et al. (8) who reported 78% and 79% probability of 8.5 yr 
survival after disease onset. 
 Our study had several limitations. First, because it was a mul-
ticenter retrospective study performed on patients who were 
diagnosed with LAM over a 18-yr period, treatment protocols 
were very diverse. And the schedules for following lung func-
tion tests were not consistent among hospitals. Thus, the effect 
of therapeutic interventions on lung function could not be eval-
uated. In addition, because the follow-up period in patients di-
agnosed with LAM since 2004 was short, we cannot compare 
and discuss the natural course of the disease. 
 In conclusion, our study showed that the clinical features of 
Korean patients with LAM do not differ from those reported 
elsewhere. Moreover, we demonstrated that the increment of 
newly diagnosed patients is the result of increase in detection 
of the early stage LAM with mild respiratory symptoms and lung 
impairment by the widespread use of chest CT screening. 
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